Shi T, Li Y, Deng C, Ren Q, Xu C*, Zhong Z*. In vivo nano-engineering T cells for CAR-T therapy. J Control Release. 2025 Nov 1:114379. doi: 10.1016/j.jconrel.2025.114379. Epub ahead of print. PMID: 41183575 Ye, R., Ren, Q., Chang, L., Zhang, S., Deng, C., Cao, L., Shi, M., Lou, B., Meng, F., Du, S., Ren, K., Piao, X., Xu, C.*, Zhong, Z.* Administration route-commended concise organ-selective mRNA transfection (ACCOST) by cyclic disulfide-primed short polyethylenimine. Nano Today, 2025 Aug; (63)102741 Ren, Q., Zhao, X., Zhou, L., Meng, F., Deng, C., Meng, F., Zhou, F., Xu, C.*, Zhong, Z.* Monocyte-Driven Lymph Node Targeting of mRNA Cancer Vaccines via Transferrin Receptor Associating Polyplexes (TRAP). Nature Biomedical Engineering, 2026 In press Binzel, D. #, Xu, C.# (co-first author), Binzel, K., Ghosh, A., Pippin, A., Li, X., Sechi, M., Knopp, M., Kumar, K., Guo, P.* RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis. RNA Nanomed, 2025 Aug 4; 2(1) Xu, C. #, Chen, R., Pu,C., Wang, W., Tang, Y., Wang, Q., An, J., ... & Zhang, L.. (2025). circDesign Algorithm for Designing Synthetic Circular RNA. bioRxiv, 2025 April.
|
Fan T#, Xu C# (co-first author), Wu J#, Cai, Y, Cao W, Shen H, Zhang M, Zhu H, Yang J, Zhu Z, Ma X, Ren J, Huang L, Li Q, Tang Y, Yu B, Chen C, Xu M, Wang Q, Xu Z, Chen F, Liang S, Zhong Z, Jamroze A, Tang DG, Li H, Dong C. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci Adv. 2024 Oct 11;10(41):eadn9961. doi: 10.1126/sciadv.adn9961.
|
Cui G, Shao Y, Wang J, Xu C*, Jinping Zhang*, Zhiyuan Zhong*, Polymersome-mediated Cbl-b silencing activates T cells against solid tumors. Biomater. Sci., 2025, doi:10.1039/D5BM00001G
|
Ye, Z., Xu, C., Zhang, Y., Zhao, Y., Xu, C.* Targeted protein degraders based on biomacromolecules: current progress and challenges. Acta Pharmaceutica Sinica, 2025, 60(11): 3309-3317.
|
Xu C, Yin H, Yudhistira T, Li Z, Binzel D,*Guo P*, Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment. RNA NanoMed, 2024, (1) 109-123.doi:10.59566/ISRNN.2024.0101109.
|
Zhang, H.#, Zhang, L.#, Lin, A. #, Xu, C. # (co-first author), Li, Z., Liu, K., ... & Huang, L. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature, 2023, 1-3.
|
Yi Fang, Jing-Xin Li, Davone Duangdany, Yang Li, Xi-Lin Guo, Chanthala Phamisith, Ming-Yun Shen, Bo Yu, Bin Luo, Yu-Zhu Wang, Si-Jun Liu, Fan-Fan Zhao, Cong-Cong Xu, Xu-Hui Qiu, Rong-Juan Pei, Jie Wang, Haifa Shen, Wu-Xiang Guan, Hang-Wen Li, Mayfong Mayxay, Safety, immunogenicity and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: interim report of a Phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos). EClinicalMedicine. 2023 Dec 13;67:102372. doi: 10.1016/j.eclinm.2023.102372.
|
Carcache PJ, Guo S, Li H, Zhang K, Xu C, Chiu W, Guo P. Regulation of reversible conformational change, size switching, and immunomodulation of RNA nanocubes. RNA. 2021 Sep 1;27(9):971-80.
|
Guo S., Xu C., Yin H., Hill J., Pi F., Guo P. (2019). Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation. WIREs Nanomedicine and Nanobiotechnology, 2019 Aug 27:e1582. doi: 10.1002/wnan.1582
|
Xu, C., Zhang, K., Yin, H., Li, Z., Krasnoslobodtsev, A., Zheng, Z., Ji, Z., Guo, S., Li, S., Chiu, W. and Guo, P., 2020. 3D RNA nanocage for encapsulation and shielding of hydrophobic biomolecules to improve the in vivo biodistribution. Nano Research, 13(12), pp.3241-3247.
|
Chen, Y., Li, J., Duangdany, D., Phamisith, C., Yu, B., Lan, S., Jin, L., Lv, D., Li, Y., Luo, B., Han, P., Wu, J., Wang, Y., Xu, C., Shen, M., Zhao, F., Liu, P., Pei, R., Shen, H., Guan, W., Li, H., Mayxay, M., Safety and Immunogenicity of SW-BIC-213, a Modified COVID-19 Lipo-Polyplex Mrna Vaccine, in Laotian Healthy Adults Aged 18 Years and Above: a Phase 1/2 Trial, Openalex, 2023
|
Xu C., Wang H., Yin H., Sechi M., Li Z., Kumar K., Tweedle M., Knopp M., Guo P. 2022. Small Molecule Conjugated RNA Nanoparticles for PET Imaging-guided Prostate Cancer Therapy, Under Submission.
|
Ghimire C, Wang H, Li H, Vieweger M, Xu C, Guo P. RNA nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity. ACS Nano. 2020 Sep 9;14(10):13180-91.
|
Li H., Wang S., Ji Z., Xu C., Shlyakhtenko L.S. and Guo P., Construction of RNA nanotubes. 2019. Nano Research, 12(8), pp.1952-1958.
|
Zheng Z, Li Z, Xu C, Guo B, Guo P. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J Control Release. 2019 Aug 22;. doi: 10.1016/j.jconrel.2019.08.021.
|
Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther. 2019 Jul 3;27(7):1252-1261. doi: 10.1016/j.ymthe.2019.04.018.
|
Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression. Redox Biol. 2019 Feb;21:101085. doi: 10.1016/j.redox.2018.101085.
|
Haque F†, Xu C†, Jasinski DL, Li H, Guo P. († Contributed equally) Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice. Methods Mol Biol. 2017;1632:359-380. doi: 10.1007/978-1-4939-7138-1_23.
|
Guo S, Xu C, Yin H, Guo P, Hill J, and Pi F. 2022. Tuning the Size, Shape, and Structure of RNA Nanoparticles for Favorable Cancer Targeting and Immunostimulation. RNA Nanotechnology and Therapeutics, pp.543-562.
|
Li W, Yang X, He L, Wang K, Wang Q, Huang J, Liu J, Wu B, Xu C. Self-Assembled DNA Nanocentipede as Multivalent Drug Carrier for Targeted Delivery. ACS Appl Mater Interfaces. 2016 Oct 5;8(39):25733-25740. doi: 10.1021/acsami.6b08210
|
